TARA Stock Analysis: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$4.05
0.07 (1.89%)
▲
5d:
+2.66%
30d:
-0.86%
90d:
-25.78%
BUY
HIGH Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 10, 2026
5d
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TARA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TARA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $4.04, which is considered fair relative to its 30-day fair value range of $3.96 to $4.18.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is approaching resistance at $4.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+569.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is approaching resistance at $4.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+569.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.96 -
$4.18
Company Quality Score
45/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 23th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 569.3% below Wall St target ($26.57)
Trading Range Analysis
30-Day Trading Range
$3.96 -
$4.18
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.63
(15.5%)
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.14
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.41
Wall Street Target
$26.57
(+569.3%)
Share & Embed Analysis
Last updated: August 04, 2026 2:03 PM ET
Data refreshes hourly during market hours. Next update: 3:03 PM
Data refreshes hourly during market hours. Next update: 3:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Jacqueline Zummo
SELL
22598 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
